咽頭炎治療市場 - 全球產業規模、佔有率、趨勢、機會及預測（按疾病類型、藥物類別、分銷管道、地區和競爭格局分類，2021-2031年）

全球咽頭炎治療市場預計將從 2025 年的 24.9 億美元成長到 2031 年的 32.7 億美元，複合年成長率為 4.65%。

這個市場主要由抗生素、皮質類固醇和鎮痛藥等藥物組成，這些藥物用於緩解咽頭炎發炎並控制發燒和喉嚨痛等症狀。推動市場擴張的關鍵因素包括全球細菌和病毒性呼吸道感染疾病的日益流行，以及患者對早期診斷重要性的認知不斷提高，從而預防風濕熱等嚴重併發症。這些潛在因素確保了治療方法的穩定需求，使其區別於處方習慣和劑型偏好的暫時性變化。

然而，市場發展面臨的主要障礙是日益嚴重的抗菌素抗藥性問題，這需要實施更嚴格的抗菌素管理方案並減少濫用抗生素。這一沉重的疾病負擔凸顯了製定有效控制策略的迫切性。英國健康與安全執行局的數據也印證了這一持續存在的挑戰，數據顯示，僅在2024年1月至3月期間，英格蘭就報告了12176例猩紅熱病例，這表明鏈球菌感染疾病的持續高發率需要得到妥善的醫療護理。

市場促進因素

全球呼吸道感染和鏈球菌感染疾病的上升趨勢是市場成長的主要驅動力，持續推高了對病原體感染疾病抗生素和緩解疼痛症狀藥物的需求。在後疫情時代，免疫力下降導致病原體快速傳播，細菌性咽喉感染疾病捲土重來，這種需求激增的趨勢特別顯著。例如，《日本時報》2024年6月一篇題為「日本嚴重鏈球菌感染疾病創歷史新高，達977例」的報導援引了日本國立感染疾病研究所的一份報告，指出截至6月初，日本已確診977例嚴重鏈球菌感染疾病病例，超過了前一年的記錄。如此高的感染率直接影響咽頭炎咽頭炎預防嚴重的後遺症。

同時，快速照護現場技術的進步和零售醫療服務的擴張正在從根本上改變醫療保健格局，使即時檢測和治療模式成為可能。這種轉變改善了醫療服務的可近性，使藥劑師能夠快速區分病毒和細菌病因，從而合理地開立抗生素處方，減少不必要的就診。根據英國國家醫療服務體系（NHS）英格蘭分部2024年1月發布的「藥局優先」（Pharmacy First）新聞稿，已有10265家社區藥局註冊推出治療七種常見疾病的服務，其中包括咽喉痛的治療。然而，滿足這種分散的需求需要一條具有韌性的供應鏈，而目前由於生產限制，這條供應鏈正面臨壓力。據美國衛生系統藥劑師協會（ASHP）稱，2024年第一季藥品短缺數量達到創紀錄的323種，凸顯了包括該領域使用的抗生素在內的基本藥物庫存面臨的嚴峻挑戰。

市場挑戰

抗菌素抗藥性日益嚴重的對全球咽頭炎治療市場構成重大挑戰，迫使人們減少抗生素處方。不斷上升的抗藥性促使監管機構和醫療機構實施更嚴格的藥物管理計劃，以維持現有藥物的療效。這些措施積極限制在未確診細菌感染的情況下對咽頭炎使用經驗性抗生素，並顯著降低這種通常由病毒引起的疾病的用藥頻率。從隨意用藥轉向標靶治療，直接限制了市場的獲利潛力。

持續的高抗藥性水準進一步凸顯了這些限制性通訊協定的必要性，確保合規要求將繼續抑制市場成長。近期監測數據表明，濫用處方箋已不再可行，凸顯了這項威脅的嚴重性。美國疾病管制與預防中心 (CDC) 於 2024 年發布的數據顯示，由抗藥性菌引起的感染疾病較疫情前基準值增加了總合%。這種抗藥性不斷增強的統計證據表明，有必要繼續採取嚴格的抗菌藥物管理干預措施，從而限制該領域藥物治療的廣泛應用。

市場趨勢

將人工智慧 (AI) 應用於非侵入性咽喉成像技術，透過智慧型手機遠端檢測鏈球菌感染疾病，正在革新早期診斷方式。這項技術無需患者親自前往醫院，即可拍攝咽喉影像，並利用機器學習演算法準確區分病毒和細菌病原體，從而消除了現場檢測的瓶頸。此類創新為咽頭炎患者提供了即時分流工具，顯著減少了不必要的就醫和抗生素濫用。根據 Mugglehead 網站 2025 年 1 月發表的題為「Light AI 開發用於診斷嚴重咽喉感染疾病的智慧型手機技術」的報導報道，Light AI 自 2024 年初以來已籌集 2500 萬加元，用於開發一種能夠以 97% 的準確率檢測 A 組鏈球菌的演算法。

同時，消費者對天然草本配方的偏好日益成長，推動止痛方式從傳統合成止痛藥轉向植物來源緩解症狀。患者越來越傾向於選擇含有高山植物、蜂蜜和薄荷醇等成分的含片和滴劑，作為更安全、副作用更少的急性咽頭炎治療方案。這種需求在新興市場尤其顯著，這些市場傳統醫學與現代零售通路融合，為成熟的草本品牌提供了強勁的銷售動力。根據利口樂公司2025年5月發布的題為「利口樂2024年業績穩健成長」的新聞稿，該公司在包括韓國、台灣和泰國在內的多個亞洲市場實現了兩位數的成長，證實了市場對植物來源咽頭炎治療產品的需求不斷成長。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球咽頭炎治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依疾病類型（急性咽頭炎、慢性咽頭炎）
  • 依藥物類別（抗生素、抗病毒藥、皮質類固醇、抗真菌藥物藥物、其他）
  • 按分銷管道（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美咽頭炎治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲咽頭炎治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區咽頭炎治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲咽頭炎治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲咽頭炎治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球咽頭炎治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc
• Novartis AG
• Amneal Pharmaceuticals LLC
• Kenvue Inc.
• Thornton & Ross Ltd
• Reckitt Benckiser Group Plc
• Honibe
• Prestige Consumer Healthcare Inc.
• Traditional Medicinals, Inc.
• Lozen Pharma Pvt. Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pharyngitis Treatment Market is expected to rise from USD 2.49 Billion in 2025 to USD 3.27 Billion by 2031 at a CAGR of 4.65%. This market centers on pharmaceutical interventions-such as antibiotics, corticosteroids, and analgesics-aimed at alleviating pharyngeal inflammation and managing symptoms like fever and sore throat. The primary forces driving this expansion include the increasing global prevalence of bacterial and viral respiratory infections, coupled with growing patient awareness regarding the importance of early diagnosis to prevent severe complications like rheumatic fever. These foundational factors guarantee a steady demand for therapeutic regimens, distinguishing them from transient changes in prescription habits or formulation preferences.

Conversely, a major obstacle hindering market development is the intensifying issue of antimicrobial resistance, which has required the implementation of stricter stewardship programs and a reduction in the indiscriminate use of antibiotics. This substantial disease burden highlights the urgent need for effective management strategies. Data from the UK Health Security Agency illustrates this persistent challenge, noting that 12,176 cases of scarlet fever were reported in England between January and March of 2024 alone, emphasizing the continuing volume of streptococcal infections that demand precise medical attention.

Market Driver

The increasing global frequency of respiratory and streptococcal infections serves as a primary catalyst for market growth, generating consistent demand for both pathogen-specific antibiotics and analgesic symptom relief. This surge is especially notable in post-pandemic environments where immunity gaps have facilitated rapid pathogen transmission and a resurgence of bacterial throat infections. For instance, a June 2024 article in The Japan Times titled 'Japan sees record 977 cases of severe strep infections' cited the National Institute of Infectious Diseases, which reported that the country documented 977 severe streptococcal infection cases by early June, exceeding the previous year's record. Such high infection rates compel healthcare systems to maintain robust inventories of therapeutic agents to treat acute pharyngeal inflammation and prevent severe sequelae, directly influencing procurement volumes for pharyngitis treatments.

At the same time, the treatment landscape is being fundamentally altered by advancements in rapid point-of-care diagnostics and the expansion of retail health services, which enable immediate test-and-treat models. This shift improves accessibility, allowing pharmacists to quickly distinguish between viral and bacterial etiology, thereby guiding appropriate antibiotic prescription and reducing unnecessary medical visits. As reported in an NHS England 'Pharmacy First' press release from January 2024, 10,265 community pharmacies registered to launch a service treating seven common conditions, specifically including sore throat management. However, meeting this decentralized demand requires a resilient supply chain, which is currently under pressure due to manufacturing constraints. The American Society of Health-System Pharmacists noted that in the first quarter of 2024, active drug shortages reached an all-time high of 323, highlighting critical inventory challenges for essential medications including antimicrobials used in this sector.

Market Challenge

The escalating problem of antimicrobial resistance acts as a significant barrier to the Global Pharyngitis Treatment Market by necessitating a reduction in the volume of antibiotic prescriptions. As resistance rates increase, regulatory agencies and healthcare institutions are enforcing stricter stewardship programs to maintain the efficacy of existing drugs. These measures actively discourage the empirical use of antibiotics for pharyngeal inflammation without confirmed bacterial etiology, significantly limiting the frequency of drug administration for a condition that is often viral. This transition from liberal prescription habits to targeted therapy directly constrains the market's revenue potential.

The persistence of high resistance levels reinforces the need for these restrictive protocols, ensuring that market growth remains dampened by compliance requirements. The severity of this threat is evident in recent surveillance data which underscores why indiscriminate prescribing is no longer viable. According to published data from the Centers for Disease Control and Prevention in 2024, infections caused by antimicrobial-resistant bacteria increased by a combined 20% compared to pre-pandemic baselines. This statistical evidence of rising resistance justifies the continued rigor of stewardship interventions, thereby capping the widespread utilization of pharmaceutical treatments in this sector.

Market Trends

The integration of Artificial Intelligence for non-invasive throat imaging is revolutionizing early diagnosis by facilitating remote, smartphone-based screening for streptococcal infections. This technology resolves the bottleneck of in-person testing by allowing patients to capture throat images which are analyzed by machine learning algorithms to distinguish between viral and bacterial etiology with high precision. Such innovations significantly reduce unnecessary clinic visits and antibiotic overuse by providing immediate, accessible triage tools for pharyngitis management. According to a January 2025 article in Mugglehead titled 'Light AI develops smartphone tech for diagnosing severe throat infection', Light AI has raised C$25 million since early 2024 to support the development of its algorithm which detects Streptococcus A with nearly 97% accuracy.

Concurrently, there is a growing consumer preference for natural and herbal formulations, driving a shift away from conventional synthetic analgesics toward plant-based symptom relief. Patients are increasingly seeking therapeutic lozenges and drops containing ingredients like alpine herbs, honey, and menthol, perceived as safer alternatives with fewer side effects for managing acute throat inflammation. This demand is particularly robust in emerging markets where traditional medicine aligns with modern retail availability, fostering strong sales for established herbal brands. According to a May 2025 press release from Ricola titled 'Ricola delivers solid results in 2024', the company achieved double-digit growth in many Asian markets such as South Korea, Taiwan, and Thailand, underscoring the expanding market demand for botanical pharyngitis treatments.

Key Market Players

• Pfizer Inc
• Novartis AG
• Amneal Pharmaceuticals LLC
• Kenvue Inc.
• Thornton & Ross Ltd
• Reckitt Benckiser Group Plc
• Honibe
• Prestige Consumer Healthcare Inc.
• Traditional Medicinals, Inc.
• Lozen Pharma Pvt. Ltd

Report Scope

In this report, the Global Pharyngitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharyngitis Treatment Market, By Disease Type

• Acute Pharyngitis
• Chronic Pharyngitis

Pharyngitis Treatment Market, By Drug Class

• Antibiotics
• Antiviral Drugs
• Corticosteroids
• Antifungals
• Others

Pharyngitis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Pharyngitis Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharyngitis Treatment Market.

Available Customizations:

Global Pharyngitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharyngitis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Acute Pharyngitis, Chronic Pharyngitis)
  • 5.2.2. By Drug Class (Antibiotics, Antiviral Drugs, Corticosteroids, Antifungals, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pharyngitis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharyngitis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Pharyngitis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Pharyngitis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel

7. Europe Pharyngitis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharyngitis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Pharyngitis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Pharyngitis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Pharyngitis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Pharyngitis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Pharyngitis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharyngitis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Pharyngitis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Pharyngitis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Pharyngitis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Pharyngitis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Pharyngitis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharyngitis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Pharyngitis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Pharyngitis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. South America Pharyngitis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharyngitis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Pharyngitis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Pharyngitis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharyngitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Amneal Pharmaceuticals LLC
• 15.4. Kenvue Inc.
• 15.5. Thornton & Ross Ltd
• 15.6. Reckitt Benckiser Group Plc
• 15.7. Honibe
• 15.8. Prestige Consumer Healthcare Inc.
• 15.9. Traditional Medicinals, Inc.
• 15.10. Lozen Pharma Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer